Published in Eur Urol on April 06, 2013
Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy. J Am Coll Surg (2016) 1.39
Extended pelvic lymph node dissection at the time of robot-assisted radical prostatectomy: Impact of surgical volume on efficacy and complications in a single-surgeon series. Can Urol Assoc J (2015) 0.89
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. World J Urol (2015) 0.83
Robot-Assisted Extended Pelvic Lymph Nodes Dissection for Prostate Cancer: Personal Surgical Technique and Outcomes. Int Braz J Urol (2016) 0.75
The "peritoneal scaffold" technique of extended pelvic lymph node dissection during radical prostatectomy: A novel technique. Indian J Urol (2016) 0.75
The robotic approach does not change the current paradigms of pelvic lymph node dissection for prostate cancer. Eur Urol (2013) 0.75
Robotic-assisted fluorescence sentinel lymph node mapping using multimodal image guidance in an animal model. Urology (2014) 0.75
Extended pelvic lymphadenectomy in prostate cancer: Practice makes perfect. Can Urol Assoc J (2015) 0.75
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol (2009) 4.58
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01
Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. Eur Urol (2008) 3.98
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93
Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol (2008) 3.83
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol (2013) 3.65
Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol (2002) 3.52
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol (2003) 3.23
Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. J Urol (2010) 3.18
A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol (2011) 3.18
Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol (2012) 3.17
Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol (2012) 3.12
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol (2011) 3.10
Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol (2011) 3.03
Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer (2011) 3.02
Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol (2010) 2.92
Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92
Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J (2006) 2.91
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol (2010) 2.79
Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. J Endourol (2014) 2.78
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. J Urol (2009) 2.77
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol (2007) 2.75
Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Predictors of immediate continence following robot-assisted radical prostatectomy. J Endourol (2012) 2.71
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2005) 2.69
da Vinci-assisted robotic partial nephrectomy: technique and results at a mean of 15 months of follow-up. Eur Urol (2006) 2.65
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2008) 2.57
Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series. Int J Radiat Oncol Biol Phys (2011) 2.55
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50
Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol (2007) 2.50
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol (2012) 2.46
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol (2011) 2.45
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol (2012) 2.43
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate cancer: surgical technique and experience with the first 99 cases. Eur Urol (2008) 2.42
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol (2010) 2.39
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int (2012) 2.37
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol (2007) 2.30
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol (2013) 2.26
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial. Eur Urol (2007) 2.24
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol (2008) 2.22
Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol (2011) 2.22
Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach. J Urol (2012) 2.22
Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy. Eur Urol (2006) 2.21
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. Urology (2011) 2.20
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Risk of incisional hernia after minimally invasive and open radical prostatectomy. J Urol (2013) 2.18